Cerus Corporation (CERS:NASDAQ) closed at $1.99 on November 13, 2026, up 2.32% on the day. The stock trades 42.8% below its 52-week high of $3.47 and 35.0% above its 52-week low of $1.47. Over the past year, it gained 22.5%. Cerus Corporation is part of the Health Care sector (Medical/Dental Instruments).
In 252 trading sessions since November 13, 2025, CERS closed higher on 119 days (47%). Its best day was May 1, 2026 (+33.99%) and its worst was July 31, 2026 (-25.61%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was founded in 1991 and is headquartered in Concord, California.
Find more stocks like CERS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.